Mode
Text Size
Log in / Sign up
Phase 4 N=190 Randomized Single-blind Treatment

Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery

Pertrochanteric Fracture

Enrolled (actual)
190
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Amount (mg) of Narcotics (Oral Morphine mg Equivalents) Used — 16; 10 morphine milligram equivalents (MME)

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Marcaine, Duramorph , ketorolac (Drug); Bupivacaine (Marcaine) (Drug); General Anesthetics (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
NYU Langone Health
Primary completion
Jun 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Amount (mg) of Narcotics (Oral Morphine mg Equivalents) Used
16; 10
PRIMARY
Ambulation Distance
48.7; 88.9
PRIMARY
Score on Visual Analogue Scale (VAS) for Pain
3.3; 2.5

Summary

This is a phase I, randomized, single-blind, placebo-controlled, single-center study of the effects of surgical site injection on pain and narcotic utilization in participants who undergo surgery for lower extremity fractures. 200 participants with lower extremity fractures who are admitted for operative fixation will be included in the study. Participants will be randomized to receive either a pain cocktail injection around the fracture site and surrounding tissues or control (no injection). An analysis of pain scores, rehabilitation progress, length of stay, narcotic utilization, and satisfaction scores will be performed.

Eligibility Criteria

Inclusion Criteria

  • Lower extremity fracture including femoral neck, intertrochanteric, sub-trochanteric, and femoral shaft fracture

Exclusion Criteria

  • Pregnant women
  • Treatment with Arthroplasty
  • Patients who receive a peripheral nerve block
  • Patients who receive intra-op or post-op ketamine
  • Patients with concomitant TBI or MR
  • Polytrauma patients
  • Pathologic Fractures
  • Patients who live greater than 10 miles from NYU or who will not be followed by an NYU provider
  • Patients with a contraindication to any of the medications on the study list due to other medical problems such as renal or liver disease or due to allergy/intolerance
  • Patients with prior extremity weakness resulting from stroke or other neurological condition
  • Prior or current history of narcotic use
  • Patients with advanced dementia
  • NYUMC Students, Residents, Faculty
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03693404). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search